Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma
- The feasibility will be evaluated in terms of objective response rate, efficacy of stem
cell collection, disease-free survival, and overall survival.
Interventional
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
objective response rate
10/2009
Hawk Kim, professor
Principal Investigator
Ulsan Universtity Hospital, ROK
Korea: Food and Drug Administration
C-012A
NCT00561301
November 2006
October 2009
Name | Location |
---|